Jonathan W. Kim
Academic Appointments
- Assistant Professor - Med Center Line, Ophthalmology
- Assistant Professor - Med Center Line (By courtesy), Otolaryngology (Head and Neck Surgery)
Contact Information
-
Clinical Offices
Ophthalmology Clinic 900 Blake Wilbur Dr W3002 MC 5353 Palo Alto, CA 94304 Tel Work (650) 736-8098 Fax (650) 725-6619Practices at Stanford Hospital and Clinics and Lucile Packard Children's Hospital
- Academic Offices
Administrative Contact Jonathan Kim Assistant Professor Email Tel Work 650-736-8098Not for medical emergencies or patient use
Professional Snapshot
Clinical Focus
- Ophthalmology
- Graves' disease
- Orbital and eyelid trauma
- Eyelid, orbital, and ocular tumors
Administrative Appointments
- Assistant Professor, Department of Ophthalmology, Stanford University Medical Center (2007 - present)
Honors and Awards
- Alpha Omega Alpha, Junior year, Alpha Medical Honor Society (06/1994)
- Heed Fellowship, Heed Ophthalmic Foundation (07/1999)
- Outstanding Thesis Award, Am Soc Oph Plastic Reconstructive Surgery (10/01)
- Resident Teaching Award, University of California, Irvine (06/2006)
- Achievement Award, American Academy of Ophthalmology (10/07)
Professional Education
| Fellowship: | Massachusetts Eye and Ear Infirmary, MA (2004) |
| Fellowship: | Oculoplastic & Orbital Surgery, Jules Stein Eye Institute, CA (2000) |
| Internship: | Mercy Hospital & Medical Ctr., CA (1995) |
| Board Certification: | Ophthalmology, American Board of Ophthalmology (2000) |
| Medical Education: | University of Iowa College of Medicine, IA (1994) |
Scientific Focus
Research Interests
Dr. Kim's current research interests include surgical reconstruction of Graves' eye disease, improving outcomes following orbital and adnexal trauma, and developing novel treatment options for introcular malignancies (e.g. retinoblastoma, uveal melanoma).
Publications
- Orbital recurrence of retinoblastoma following enucleation. Br J Ophthalmol. 2009; (4): 463-7
- Published international classification of retinoblastoma (ICRB) definitions contain inconsistencies--an analysis of impact. Ophthalmic Genet. 2009; (1): 40-4
- Persistence of retinal function after selective ophthalmic artery chemotherapy infusion for retinoblastoma. Doc Ophthalmol. 2009; (1): 13-22
- Fibrin sealant for retinoblastoma: where are we? J Ocul Pharmacol Ther. 2008; (5): 433-8
- A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology. 2008; (8): 1398-404, 1404.e1
Help
Ophthalmology Internal